Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25718332 | 0.92 | IDO1 (0.32) | IDO1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL26771643 | 0.89 | NR1I2 (0.36) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL21164273 | 0.88 | ALDH1A1 (0.33) | IDO1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL22601334 | 0.79 | ACHE (0.33) | IDO1NPC1RAB9AALDH1A1HTT | |
| SCHEMBL23891423 | 0.79 | ACHE (0.43) | — | |
| SCHEMBL20122136 | 0.79 | NR1I2 (0.36) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL23172210 | 0.79 | NR1I2 (0.36) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL18948523 | 0.79 | NR1I2 (0.36) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20229648 | 0.78 | ACHE (0.33) | IDO1 | |
| SCHEMBL21566438 | 0.77 | NR1I2 (0.35) | NPC1RAB9AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| EP-2938344-B1 | PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322785-A1 | ADENOSINE A2A AND A2B RECEPTOR DUAL ANTAGONISTS FOR IMMUNO-ONCOLOGY | ADORA2A, ADORA2B, ADORA1 | IDO1 31/4885NPC1 2712/4885RAB9A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.